Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results - read this article along with other careers information, tips and advice on BioSpace
Share:
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ( Navidea or the Company ), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the granting of a National Institutes of Health ( NIH ) award to the University of California San Diego School of Medicine for the proposal entitled, Renal Molecular Imaging of Mesangial Cell Function with Tc-99m-Tilmanocept. The award (Project Number: 1R01DK127201-01), from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, was granted to Co-Principal Investigators UC San Diego faculty Carl Hoh, MD and David Vera, PhD, of the Department of Radiology, and Charles Ginsberg, MD, MAS, of the Department of Medicine, Division of Nephrology.